We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
BioTelemetry (BEAT - Free Report) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session. This change lagged the S&P 500's 0.76% gain on the day. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, added 0.71%.
Heading into today, shares of the heart monitoring device maker had gained 17.68% over the past month, outpacing the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 28, 2019. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.02 million, up 12.29% from the year-ago period.
Any recent changes to analyst estimates for BEAT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT currently has a Zacks Rank of #1 (Strong Buy).
In terms of valuation, BEAT is currently trading at a Forward P/E ratio of 39.04. This represents a premium compared to its industry's average Forward P/E of 19.94.
Investors should also note that BEAT has a PEG ratio of 3.9 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BEAT's industry had an average PEG ratio of 1.54 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know
BioTelemetry (BEAT - Free Report) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session. This change lagged the S&P 500's 0.76% gain on the day. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, added 0.71%.
Heading into today, shares of the heart monitoring device maker had gained 17.68% over the past month, outpacing the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.
Wall Street will be looking for positivity from BEAT as it approaches its next earnings report date. This is expected to be February 28, 2019. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.02 million, up 12.29% from the year-ago period.
Any recent changes to analyst estimates for BEAT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT currently has a Zacks Rank of #1 (Strong Buy).
In terms of valuation, BEAT is currently trading at a Forward P/E ratio of 39.04. This represents a premium compared to its industry's average Forward P/E of 19.94.
Investors should also note that BEAT has a PEG ratio of 3.9 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BEAT's industry had an average PEG ratio of 1.54 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.